Diego Signorelli

List of Publications by Year in Descending Order

51 papers	1,209 citations	21 h-index	34 g-index
52 ext. papers	1,605 ext. citations	4.5 avg, IF	4.09 L-index

#	Paper	IF	Citations
51	Post-progression outcomes of NSCLC patients with PD-L1 expression ≥50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. *European Journal of Cancer*, **2021**, 148, 24-35	7.5	8
50	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. *Translational Lung Cancer Research*, **2021**, 10, 2955-2969	4.4	0
49	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. *Clinical Lung Cancer*, **2021**, 22, e180-e192	4.9	5
48	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer*, **2021**, 152, 165-173	5.9	11
47	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. *Journal of Thoracic Oncology*, **2021**, 16, 1298-1311	8.9	5
46	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	11
45	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥50. *Cancer Immunology, Immunotherapy*, **2020**, 69, 2209-2221	7.4	32
44	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clinical Lung Cancer*, **2020**, 21, e337-e348	4.9	4
43	Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *Cancers*, **2020**, 12,	6.6	73
42	mutations confer poor prognosis in malignant pleural mesothelioma. *Translational Lung Cancer Research*, **2020**, 9, 1940-1951	4.4	
41	SMO mutations confer poor prognosis in malignant pleural mesothelioma. *Translational Lung Cancer Research*, **2020**, 9, 1940-1951	4.4	0
40	Facing the First-line in Metastatic Non-small-cell Lung Cancer Immunotherapy and Chemotherapy. *European Oncology and Haematology*, **2020**, 16, 39	0.1	
39	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. *Lung Cancer*, **2020**, 140, 59-64	5.9	22
38	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%. *Journal of Immunotherapy*, **2020**, 43, 299-306	5	10
37	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.. *JCO Precision Oncology*, **2020**, 4, 829-840	3.6	5
36	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. *Translational Lung Cancer Research*, **2020**, 9, 617-628	4.4	3
35	mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. *ESMO Open*, **2020**, 5, e000748	6	1

34	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. *Translational Lung Cancer Research*, **2020**, 9, 1533-1542	4.4	21
33	Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. *Tumori*, **2019**, 105, NP57-NP62	1.7	4
32	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. *Lung Cancer*, **2019**, 137, 38-42	5.9	29
31	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. *BioMed Research International*, **2019**, 2019, 9056417	3	28
30	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. *Lung Cancer*, **2019**, 132, 72-78	5.9	34
29	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open*, **2019**, 4, e000457	6	93
28	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. *Cancer Treatment Reviews*, **2019**, 75, 39-51	14.4	85
27	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. *Lung Cancer*, **2019**, 132, 17-23	5.9	11
26	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. *Cancers*, **2019**, 11,	6.6	10
25	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. *Future Oncology*, **2019**, 15, 2743-2757	3.6	5
24	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. *Clinical Lung Cancer*, **2019**, 20, e652-e660	4.9	2
23	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. *European Journal of Cancer*, **2019**, 123, 72-80	7.5	34
22	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort. *Journal of Thoracic Disease*, **2019**, 11, 4972-4981	2.6	15
21	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer **2019**, 7, 316		56
20	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. *Cancers*, **2019**, 11,	6.6	39
19	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clinical Cancer Research*, **2019**, 25, 989-999	12.9	213
18	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. *Clinical Cancer Research*, **2019**, 25, 2166-2173	12.9	47
17	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. *Clinical Lung Cancer*, **2019**, 20, e413-e417	4.9	15

16	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. *Lung Cancer*, **2018**, 115, 135-142	5.9	23
15	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. *Targeted Oncology*, **2018**, 13, 795-800	5	14
14	Cognitive impairment and chemotherapy: a brief overview. *Critical Reviews in Oncology/Hematology* , **2017**, 118, 7-14	7	44
13	Concomitant rearrangement and mutation in non-small cell lung cancer patients: a literature review of 100 cases. *Oncotarget*, **2017**, 8, 59889-59900	3.3	26
12	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. *Current Drug Targets*, **2017**, 18, 341-362	3	7
11	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumor Biology*, **2016**, 37, 12991-13003	2.9	12
10	Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?. *Tumori*, **2016**, 102, 18-30	1.7	8
9	Treatment of lung large cell neuroendocrine carcinoma. *Tumor Biology*, **2016**, 37, 7047-57	2.9	34
8	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. *Translational Lung Cancer Research*, **2016**, 5, 563-578	4.4	28
7	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. *PLoS ONE*, **2016**, 11, e0157751	3.7	14
6	Diagnosis and management of typical and atypical lung carcinoids. *Critical Reviews in Oncology/Hematology*, **2016**, 100, 167-76	7	26
5	Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation. *Oncology*, **2015**, 89, 227-34	3.6	9
4	Cardiac Metastasis from Renal Cell Carcinoma Successfully Treated with Pazopanib: Impact of TKIsS Antiangiogenic Activity. *Tumori*, **2014**, 100, e298-e300	1.7	5
3	Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIsS antiangiogenic activity. *Tumori*, **2014**, 100, e298-300	1.7	5
2	Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. *BMC Musculoskeletal Disorders*, **2010**, 11, 34	2.8	22
1	Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥50%		1